结核流行区接受抗TNF治疗的炎症性肠病患者:靶向与全员结核预防性治疗的比较
多中心回顾性队列研究纳入中国18家医院1968例接受英夫利西单抗治疗的炎症性肠病患者,比较靶向与全员结核预防性治疗。两组活动性结核发生率无显著差异,但靶向组预防性治疗相关不良事件显著更少,支持在结核流行区启动抗TNF治疗时采用靶向预防策略。
要点
- 结核流行区接受抗TNF治疗前应筛查潜伏结核,仅阳性者给予预防性治疗。
- 靶向策略与全员预防相比未增加活动性结核风险。
- 靶向策略显著减少预防性治疗相关不良事件。
核心结论
- 在结核流行区接受英夫利西单抗治疗的炎症性肠病患者中,全员结核预防性治疗与靶向策略相比未降低活动性结核风险,且不良事件更常见。
研究设计与样本
- 多中心回顾性队列研究,纳入中国18家医院2009至2017年接受英夫利西单抗治疗的1968例成人炎症性肠病患者。
- 靶向策略组1433例,全员预防组483例,平均随访1.07±0.87年,总随访2102患者年。
主要发现
- 靶向组与全员组活动性结核发生率分别为673.3/10万人年与891.5/10万人年,差异无统计学意义(P=0.60)。
- 靶向组55/1433例接受结核预防性治疗,全员组483/483例均接受。
- 预防性治疗相关不良事件靶向组0.35%(5/1433),全员组6.8%(33/483),差异有统计学意义(P<0.05)。
临床怎么用
- 在结核流行区启动抗TNF治疗前应进行结核筛查,仅对潜伏结核筛查阳性者给予预防性治疗。
局限性
- 为回顾性队列研究,可能存在混杂因素。
- 平均随访时间较短(1.07±0.87年)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-tumour necrosis factor (anti-TNF) therapy increases the risk of tuberculosis (TB). Given limitations of screening techniques, it remains uncertain if patients receiving anti-TNF in TB endemic regions should be screened for latent infection with chemoprophylaxis restricted to those with proven infection, or if all patients should receive chemoprophylaxis. AIMS: To compare the incidence of active TB with infliximab (IFX) following targeted and universal TB chemoprophylaxis, and to determine the rates of adverse events (AE) related to TB chemoprophylaxis METHODS: A multi-centre retrospective cohort study was performed at 18 hospitals in China of 1968 adult patients with IBD receiving IFX from 2009 to 2017. TB screening prior to IFX was performed with chest X-ray and/or computed tomography [CT] and immune reactivity testing (interferon-γ release assay and/or tuberculin skin test). Patients were followed-up for a minimum of 3 months after IFX discontinuation, or until last hospital visit if IFX therapy was ongoing. Targeted strategy was defined as TB chemoprophylaxis only for patients with a positive latent TB screen, with universal strategy defined as TB chemoprophylaxis for all patients. RESULTS: Mean follow-up was 1.07 ± 0.87 years with a total follow-up of 2102 patient-years. There were 1433 patients in the targeted and 483 patients in the universal TB chemoprophylaxis groups, with no significant difference in the incidence rates of active TB between groups (673.3 per 100 000 population per year vs 891.5 per 100 000 population per year, P = 0.60). In the targeted group, 55/1433 patients received TB chemoprophylaxis compared with 483/483 in the universal group, with significantly fewer AEs related to TB chemoprophylaxis in the targeted compared to the universal group (0.35% (5/1433) vs 6.8% (33/483), P < 0.05). CONCLUSIONS: In this study of patients receiving IFX in a TB endemic area, universal chemoprophylaxis was not associated with a reduced risk of active TB when compared to a targeted chemoprophylaxis strategy, and AEs were more common. This supports the use of targeted TB chemoprophylaxis when anti-TNF therapy is initiated in TB endemic regions.
引用
- Ye L, Chapman TP, Wen Z, et al. Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region. Aliment Pharmacol Ther. 2020. PMID: 33314259. doi:10.1111/apt.16130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。